12:00 AM
 | 
Apr 11, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Mipomersen: Additional Phase III data

Additional data from a double-blind, international Phase III trial in 58 patients with severe hypercholesterolemia showed that once-weekly subcutaneous injections of 200 mg mipomersen for 26 weeks significantly reduced APOB by 36% vs. an 11% increase for placebo (p<0.001). Mipomersen also significantly reduced total cholesterol and non-HDL cholesterol by 28% and 34%,...

Read the full 239 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >